The manufacture of mesoporous silica in combination with anti-EGFR in the form of cetuximab was also carried out to deliver siRNA against polo-like kinase 1 (PLK1), which is critical in lung cancer mitosis. This evidence concerns the gene PLK1 and lung carcinoma.